Houda Alachkar, assistant professor of clinical pharmacy at the USC School of Pharmacy, was awarded a five-year, $1.79 million National Institutes of Health (NIH) grant to fund a study that could lead to advancements in the development of personalized treatments for acute myeloid leukemia.

The project is entitled “Leveraging the TCR Repertoire to identify target neoantigens in FLT3-ITD positive Acute Myeloid Leukemia.”

To continue reading this story, click here.